As mentioned above, AF patients with high levels of HSPB1 at baseline and who were treated for 3 months with the HSP-inducing compound L-glutamine showed significant reduction in serum HSPB1 levels accompanied with normalization of metabolite levels compared with patients with low HSP levels at baseline. This evidence concerns the gene HSPB1 and atrial fibrillation.